Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, lefamulin (Xenleta®) cannot be endorsed for use within NHS Wales for the treatment of community-acquired pneumonia (CAP) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of CAP or when these have failed. Please refer to the AWMSG position statement on the appraisal of antimicrobial medicines. |
||
|
||
Medicine details |
||
| Medicine name | lefamulin (Xenleta®) | |
| Formulation | 600 mg film-coated tablet | |
| Reference number | 3123 | |
| Indication | Treatment of community-acquired pneumonia (CAP) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of CAP or when these have failed |
|
| Company | Nabriva Therapeutics AG | |
| BNF chapter | Infections | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 02/02/2021 | |
| Further information AWMSG position statement on the appraisal of antimicrobial medicines |
||